Exact Sciences Corporation, Madison, Wisconsin.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
Clin Gastroenterol Hepatol. 2020 Apr;18(4):864-871. doi: 10.1016/j.cgh.2019.07.057. Epub 2019 Aug 5.
BACKGROUND & AIMS: We aimed to compare the incidence of aerodigestive cancers in persons with negative results from colonoscopies and positive vs negative results from multitarget stool DNA tests for colorectal cancer and vs expected incidence.
We performed a retrospective cohort study of 1216 subjects with comprehensive patient records and/or cancer registry data from 3 medical centers in North America. Subjects had no neoplasia or only nonadvanced adenomas, based on screening colonoscopy, and either negative results (concordant with colonoscopy, n = 1011) or positive results (discordant colonoscopy, n = 205) from the multitarget stool DNA test. Outcomes included aerodigestive cancers in discordant vs concordant groups and comparison of observed aerodigestive cancer incidence between the groups and compared with expected incidence for the population, based on the Surveillance, Epidemiology, and End Results (SEER) data.
Median follow-up times were comparable between subjects in the discordant (5.3 y; interquartile range, 3.5-5.8 y) and concordant (5.4 y; interquartile range, 3.7-5.8 y) groups. Aerodigestive cancers developed in 5 subjects in the discordant group vs 11 subjects in the concordant group (crude risk ratio, 2.3; 95% CI, 0.8-6.6; adjusted risk ratio, 2.2; 95% CI, 0.8-6.2; P = .151). The incidence of aerodigestive cancer was lower in the concordant group than the expected incidence based on SEER data (risk ratio, 0.4; 95% CI, 0.2-0.6; P = .0008). The incidence of aerodigestive cancer was not significantly greater in the population in the discordant group than the expected incidence based on SEER data (risk ratio, 0.8; 95% CI, 0.3-1.9; P = .599).
In a retrospective study with a median follow-up time of 5.4 years, incident aerodigestive cancers were uncommon among subjects with negative findings from colonoscopies, regardless of discordant or concordant results from multitarget stool DNA tests. Patients with negative results from high-quality colonoscopies therefore should not undergo further testing.
我们旨在比较结肠镜检查阴性和粪便多靶点 DNA 检测阳性与阴性结果以及预期发病率的人群中 Aerodigestive 癌症的发病率。
我们对来自北美 3 家医疗中心的 1216 名具有完整患者记录和/或癌症登记数据的受试者进行了回顾性队列研究。根据筛查性结肠镜检查,受试者没有肿瘤或仅有非晚期腺瘤,且粪便多靶点 DNA 检测结果为阴性(与结肠镜检查一致,n=1011)或阳性(与结肠镜检查不一致,n=205)。结果包括在不一致组和一致组中 Aerodigestive 癌症的发生情况,以及基于监测、流行病学和最终结果(SEER)数据,比较两组的 Aerodigestive 癌症发生率与人群的预期发病率。
在不一致组(5.3 年;四分位间距,3.5-5.8 年)和一致组(5.4 年;四分位间距,3.7-5.8 年)的受试者中,中位随访时间相当。在不一致组中,有 5 名受试者发生 Aerodigestive 癌症,而在一致组中有 11 名受试者发生 Aerodigestive 癌症(粗风险比,2.3;95%CI,0.8-6.6;调整风险比,2.2;95%CI,0.8-6.2;P=0.151)。与 SEER 数据相比,一致组的 Aerodigestive 癌症发病率较低(风险比,0.4;95%CI,0.2-0.6;P=0.0008)。与 SEER 数据相比,不一致组人群中 Aerodigestive 癌症的发病率并没有显著增加(风险比,0.8;95%CI,0.3-1.9;P=0.599)。
在一项中位随访时间为 5.4 年的回顾性研究中,结肠镜检查阴性的受试者 Aerodigestive 癌症的发生率较低,无论粪便多靶点 DNA 检测结果是一致还是不一致。因此,对于结肠镜检查质量高的阴性结果患者,不应进行进一步检查。